Bank of America upgrades NuVasive shares to ‘neutral’ rating — 5 points

Bank of America upgraded NuVasive shares from an “underperform” rating on Dec. 11, according to MidSouth News & Analysis.

Advertisement

Here are five points:

 

1. Bank of America put a $56 price objective on NuVasive’s stock.

 

2. NuVasive shares traded up 1.94 percent to $52.55.

 

3. The company has a 12-month low of $41.52 and a 12-month high of $56.61.

 

4. NuVasive’s price-to-earnings ratio is 43.04 and its market cap is $2.58 billion.

 

5. The 50-day moving average is $50.83 and the 200-day moving average is $50.86.

 

More articles on devices:
Did Loma Linda’s orthopedic device rep-less strategy work? 5 things to know
Could the medical device excise tax actually go away in the tax cuts package? 5 key notes
Exactech director sells 1.5k shares — 5 facts

 

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.